Reshaping the interventional treatment of venous in-stent restenosis and native vessel obstructions.
InterVene, Inc. is a trailblazing medical device company focused on bringing innovative technologies to treat the persistent challenges related to venous in-stent restenosis (ISR) and residual thrombotic venous obstructions and occlusions that current therapies fail to address.
Reshaping the interventional treatment of venous in-stent restenosis and native vessel obstructions.
InterVene, Inc. is a trailblazing medical device company focused on bringing innovative technologies to treat the persistent challenges related to venous in-stent restenosis (ISR) and residual thrombotic venous obstructions and occlusions that current therapies fail to address.
Addressing Significant Unmet Needs in Venous Disease
Areas of Treatment
InterVene, Inc. has developed the first fully integrated mechanical thrombectomy system designed to address the challenges associated with venous in-stent restenosis and native vessel residual thrombotic obstructions and occlusions.
Clinical Findings of Postthrombotic Syndrome (PTS)
Postthrombotic syndrome (PTS), the long-term sequela of deep vein thrombosis, is an uncurable condition with limited treatment options. 6,7
Patients with PTS experience persistent leg swelling, pain and skin changes, including venous legs ulcers in the most severe cases. 6
PTS is a potentially debilitating condition with no definitive cure. Conservative treatment methods include anticoagulation therapy, elastic compression stockings, leg elevation, lifestyle changes. 8
